A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...
The epidemiology of tumor lysis syndrome is evolving with the introduction of newer therapies. The occurrence of tumor lysis syndrome has become a less predictable but increasingly important aspect of ...
Evaluating quality of life improvements in radiation cystitis and head and neck cancer patients following hyperbaric oxygen therapy. Longitudinal analysis of cancer symptom clusters and inflammatory ...
Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL). Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia ...
Extended ibrutinib and venetoclax therapy improves outcomes in R/R CLL, with a 40% complete response rate and high survival rates. A six-month ibrutinib lead-in reduces tumor burden and tumor lysis ...
Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say. Venetoclax (Venclexta; Abbvie/Genentech) is a highly ...
Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results